UAB Comprehensive Diabetes Center (UCDC) Associate Director W. Timothy Garvey, M.D., and collaborators recently published “Cardiometabolic Disease Staging and Major Adverse Cardiovascular Event Prediction in 2 Prospective Cohorts” in the journal JACC: Advances.
Garvey is also principal investigator of the NIH-funded UAB Diabetes Research Center and a professor in the Department of Nutrition Sciences.
Authors note the purpose of their study was to “examine whether a modified cardiometabolic disease staging (CMDS) system, a validated diabetes prediction model, predicts major adverse cardiovascular events (MACE).”
Researchers defined MACE as cardiovascular death, nonfatal myocardial infarction, and/or nonfatal stroke.
Clinical parameters considered in the modified CMDS include factors like glucose, body mass index (BMI), diabetes, smoking, and more. The CMDS was originally developed to predict diabetes onset, but in this study it performed similarly or better than two commonly known cardiovascular disease prediction risk tools: the Pooled Cohort Risk Equation and the Framingham Risk Score.